A Clinical Study on the Effect of Different-Dose Rosuvastatin Therapy on Coronary Slow Flow

YE Liao-sha; SHI Yu-jie; LI Jun-xia; ZHANG Jian; SUN Qi

doi:10.3969/j.issn.1002-3429.2015.01.035

Abstract：Objective To evaluate the effect of different-dose rosuvastatin therapy on coronary slow flow (CSF). Methods 90 patients were enrolled in our hospital during Jan 2010 and Jan 2013, diagnosed as having coronary slow flow by coronary angiography. They were randomized into high dose rosuvastatin group ( high dose group) , low dose rosuvastatin group ( low dose group) and control group ( n=30 each) . Rosuvastatin 20 mg/d, rosuvastatin 10 mg/d and placebo were given to the first two groups and the control group was only given conventional therapy. The course of the therapy was 4 weeks and M-TFC value was used to compare the coronary blood flow among different groups. The effect rates of therapies on angina in different groups were also evaluated. Results 4 weeks after treatment, level of M-TFC in all the groups were decreased sig-nificantly. Levels of M-TFC in both high dose group and low dose group were significantly lower than that in control group, and the level in high dose group was significantly lower than that in low dose group (P<0. 01). The effect rates of high dose group and low dose group were significantly higher than that of control group (χ2 =6. 2388, P=0. 0125; χ2 =4. 8000, P=0. 0285). There was no difference in the effect rates between high dose group and low dose group (χ2 =0. 0113, P =0. 7386 ) . Conclusion For patients with coronary slow flow, rosuvastatin therapy, based on the conventional medication, can significantly improve the coronary blood flow velocity and increase the effect rate in treatment of angina. Intensive rosuvastatin therapy with 20 mg/d is more effective for the patients with coronary slow flow.